← Issue №10/ week of Sep 6, 2026/Hepatology

Do Patients on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Require Longer Fasting Prior to Vibration Controlled Transient Elastography?

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=23 · Sep 1, 2026 · Am J Gastro · IF 9.8

Do Patients on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Require Longer Fasting Prior to Vibration Controlled Transient Elastography?

New evidencebiomarkerbasic sciencetranslational
Clinical takeawayContinue current 3-hour fasting for VCTE in GLP-1 RA users, but extend to 4 hours if baseline LSM is critical or results are borderline, especially in patients with cirrhosis.
What it foundLSM increased 20.6% at 30-60 minutes post-meal but returned to <10% by 3 hours in GLP-1 RA users, including 12 with cirrhosis, with most returning to baseline by 3-4 hours.
ContextConfirms current fasting guidance remains generally adequate for GLP-1 RA users, though extends the possible window to 4 hours for select cases, particularly those with cirrhosis.
Refinessuggested applicable standard· Gorgojo-Martínez JJ, et al. 'Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus,' Journal of Clinical Medicine, 2022

Decision at stakefasting duration before vibration controlled transient elastography in patients on GLP-1 receptor agonists

Manage GLP-1 receptor agonist GI symptoms with slow titration per package insert, dietary modification (small frequent meals, low-fat, low-fiber initially, avoid alcohol), and hydration; treat nausea with PRN ondansetron and consider dose reduction, constipation with hydration/fiber/PEG, and reflux with an H2 blocker or PPI.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Manage GLP-1 receptor agonist GI symptoms with slow titration per package insert, dietary modification (small frequent meals, low-fat, low-fiber initially, avoid alcohol), and hydration; treat nausea with PRN ondansetron and consider dose reduction, constipation with hydration/fiber/PEG, and reflux with an H2 blocker or PPI. Discontinue the drug for severe persistent nausea/vomiting, suspected acute pancreatitis, or severe weight loss with malnutrition, and evaluate red-flag presentations for pancreatitis, obstruction/ileus, or failure to thrive; for suspected gallbladder disease (cholelithiasis/cholecystitis), obtain gallbladder studies and clinical follow-up rather than mandatory discontinuation. Do not routinely check lipase; hold and evaluate only if symptoms suggest pancreatitis.

Gorgojo-Martínez JJ, et al. 'Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus,' Journal of Clinical Medicine, 2022 · reviewed 2026-07-23 ↗
Sandhu S … Goldberg DS · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues